Computer-aided drug design software specialist Oxford Molecular Group Plc has reported pre-tax losses for the year to December 31 of 3.7m British pounds up from 3m pounds last year, but turnover soared 124% to 6m pounds. Revenue figures, however, have been bolstered by 2m pounds from acquisitions. During the period, the Oxford-based company got a major boost with a loan from Silicon Graphics Inc of the workstations it needed for its collaborative molecular modeling software work with Glaxo Wellcome Plc (CI No 2,698). In his statement chairman Roderick Hall said he expected similar partnerships with other pharmaceutical companies would be initiated this year.
